surmount-1 trial tirzepatide non-diabetic weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers GLP-1 drugs produce real weight

If refilled later than 45 days, pricing reverts to the standard (higher) cost

In clinical trial data, weight loss has been observed to develop progressively over several months of consistent use, with more meaningful changes typically emerging after the target maintenance dose is reached

It supports tissue repair, inflammation modulation, and regenerative signaling across muscles, tendons, ligaments, and the gut lining, making it a focus for research in angiogenesis research, injury tissue

Dairy Free Gluten Free Soy Free Non-GMO Preservative Free Corn Free

Industry standard : Most research peptide suppliers use 5mg as base size

Studies suggest it may support cellular longevity, enhance immune function, regulate circadian rhythms, and influence various cellular processes related to aging